178 related articles for article (PubMed ID: 30190025)
1. Novel Approaches in Waldenström Macroglobulinemia.
Spinner MA; Varma G; Advani RH
Hematol Oncol Clin North Am; 2018 Oct; 32(5):875-890. PubMed ID: 30190025
[TBL] [Abstract][Full Text] [Related]
2. Waldenstrom macroglobulinemia cells devoid of BTK
Paulus A; Akhtar S; Yousaf H; Manna A; Paulus SM; Bashir Y; Caulfield TR; Kuranz-Blake M; Chitta K; Wang X; Asmann Y; Hudec R; Springer W; Ailawadhi S; Chanan-Khan A
Blood Cancer J; 2017 May; 7(5):e565. PubMed ID: 28548645
[TBL] [Abstract][Full Text] [Related]
3. Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.
Magierowicz M; Tomowiak C; Leleu X; Poulain S
Hematol Oncol Clin North Am; 2018 Oct; 32(5):753-763. PubMed ID: 30190015
[TBL] [Abstract][Full Text] [Related]
4. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.
Xu L; Tsakmaklis N; Yang G; Chen JG; Liu X; Demos M; Kofides A; Patterson CJ; Meid K; Gustine J; Dubeau T; Palomba ML; Advani R; Castillo JJ; Furman RR; Hunter ZR; Treon SP
Blood; 2017 May; 129(18):2519-2525. PubMed ID: 28235842
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Tsakmaklis N; Kanan S; Castillo JJ; Treon SP
Br J Haematol; 2015 Mar; 168(5):701-7. PubMed ID: 25371371
[TBL] [Abstract][Full Text] [Related]
6. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Patterson CJ; Tsakmaklis N; Kanan S; Rodig S; Castillo JJ; Treon SP
Leukemia; 2015 Jan; 29(1):169-76. PubMed ID: 24912431
[TBL] [Abstract][Full Text] [Related]
7. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.
Castillo JJ; Hunter ZR; Yang G; Treon SP
Expert Rev Hematol; 2017 Aug; 10(8):739-744. PubMed ID: 28617062
[TBL] [Abstract][Full Text] [Related]
8. Genomic Landscape of Waldenström Macroglobulinemia.
Treon SP; Xu L; Liu X; Hunter ZR; Yang G; Castillo JJ
Hematol Oncol Clin North Am; 2018 Oct; 32(5):745-752. PubMed ID: 30190014
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic targets in Waldenstrom macroglobulinemia.
Paulus A; Ailawadhi S; Chanan-Khan A
Best Pract Res Clin Haematol; 2016 Jun; 29(2):216-228. PubMed ID: 27825468
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Anticancer Ther; 2015; 15(10):1143-56. PubMed ID: 26196236
[TBL] [Abstract][Full Text] [Related]
11. Current and Emerging Treatments for Waldenström Macroglobulinemia.
Grimont CN; Castillo Almeida NE; Gertz MA
Acta Haematol; 2021; 144(2):146-157. PubMed ID: 32810857
[TBL] [Abstract][Full Text] [Related]
12. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.
Paulus A; Akhtar S; Caulfield TR; Samuel K; Yousaf H; Bashir Y; Paulus SM; Tran D; Hudec R; Cogen D; Jiang J; Edenfield B; Novak A; Ansell SM; Witzig T; Martin P; Coleman M; Roy V; Ailawadhi S; Chitta K; Linder S; Chanan-Khan A
Blood Cancer J; 2016 Nov; 6(11):e492. PubMed ID: 27813535
[TBL] [Abstract][Full Text] [Related]
13. microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
Roccaro AM; Sacco A; Chen C; Runnels J; Leleu X; Azab F; Azab AK; Jia X; Ngo HT; Melhem MR; Burwick N; Varticovski L; Novina CD; Rollins BJ; Anderson KC; Ghobrial IM
Blood; 2009 Apr; 113(18):4391-402. PubMed ID: 19074725
[TBL] [Abstract][Full Text] [Related]
14. How Recent Advances in Biology of Waldenström's Macroglobulinemia May Affect Therapy Strategy.
Baron M; Simon L; Poulain S; Leblond V
Curr Oncol Rep; 2019 Feb; 21(3):27. PubMed ID: 30806816
[TBL] [Abstract][Full Text] [Related]
15. Advances in Treatment of Waldenström Macroglobulinemia.
Durot E; Tomowiak C
Curr Oncol Rep; 2023 Nov; 25(11):1375-1386. PubMed ID: 37855849
[TBL] [Abstract][Full Text] [Related]
16. The Bone Marrow Microenvironment in Waldenström Macroglobulinemia.
Jalali S; Ansell SM
Hematol Oncol Clin North Am; 2018 Oct; 32(5):777-786. PubMed ID: 30190017
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia.
Lim KJC; Tam CS
Expert Opin Pharmacother; 2020 Sep; 21(13):1555-1564. PubMed ID: 32603202
[TBL] [Abstract][Full Text] [Related]
18. Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia.
Jiménez C; Chan GG; Xu L; Tsakmaklis N; Kofides A; Demos MG; Chen J; Liu X; Munshi M; Yang G; Castillo JJ; Wiestner A; García-Sanz R; Treon SP; Hunter ZR
Br J Haematol; 2020 Jun; 189(6):1165-1170. PubMed ID: 32103491
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
Treon SP; Gustine J; Meid K; Yang G; Xu L; Liu X; Demos M; Kofides A; Tsakmaklis N; Chen JG; Munshi M; Chan G; Dubeau T; Raje N; Yee A; O'Donnell E; Hunter ZR; Castillo JJ
J Clin Oncol; 2018 Sep; 36(27):2755-2761. PubMed ID: 30044692
[TBL] [Abstract][Full Text] [Related]
20.
Gustine JN; Xu L; Tsakmaklis N; Demos MG; Kofides A; Chen JG; Liu X; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Keezer A; Meid K; Dubeau T; Yang G; Hunter ZR; Treon SP; Castillo JJ
Blood Adv; 2019 Oct; 3(19):2800-2803. PubMed ID: 31570491
[No Abstract] [Full Text] [Related]
[Next] [New Search]